Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma : results from the phase II nonrandomized KEYNOTE-059 study

Thumbnail Image
Files
Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal.pdf(641.16 KB)
Date
2019
Authors
Show 9 more
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Description
Keywords
Citation
URI
https://doi.org/10.1007/s10120-018-00909-5
 https://repositorio.uc.cl/handle/11534/60298
Collections
Artículos de revistas